24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

Published:2019-01 Issue:1 Volume:14 Page:124-129
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Borghaei Hossein,Langer Corey J.,Gadgeel Shirish,Papadimitrakopoulou Vassiliki A.,Patnaik Amita,Powell Steven F.,Gentzler Ryan D.,Martins Renato G.,Stevenson James P.,Jalal Shadia I.,Panwalkar Amit,Yang James Chih-Hsin,Gubens Matthew,Sequist Lecia V.,Awad Mark M.,Fiore Joseph,Saraf Sanatan,Keller Steven M.,Gandhi Leena

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference10 articles.

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Non-small cell lung cancer. Version 2.2018. https://www.nccn.org. Accessed January 3, 2018.

2. Pembrolizumab versus chemotherapy for PD-L1-positive non–small-cell lung cancer;Reck;N Engl J Med,2016

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

4. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?;Apetoh;Ann Oncol,2015

5. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study;Langer;Lancet Oncol,2016

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer;Cochrane Database of Systematic Reviews;2024-08-13

2. Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy;Journal of Oncology Pharmacy Practice;2024-07-26

3. Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer;Cancers;2024-06-26

4. Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome;npj Precision Oncology;2024-06-19

5. Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis;JNCI: Journal of the National Cancer Institute;2024-06-17